Skip to main content
. Author manuscript; available in PMC: 2011 Mar 18.
Published in final edited form as: Adv Drug Deliv Rev. 2009 Nov 24;62(4-5):518–531. doi: 10.1016/j.addr.2009.11.021

Table 5.

Binding and cell activation by fMLF-PEG bioconjugate-based nanocarriers [99]

Competitor Avidity: Kd (nM) Cell activation: EC50 (nM) Relative avidity: Kd × no. of fMLF Avidity/activation: EC50/Kd
fMLF 28 4.7 28 0.168
B8-PEG-fMLF1.1 190 - 209 -
B3-PEG-fMLF3 1.9 9.6 5.7 5.05
B4-PEG-fMLF4 0.8 5.0 3.2 6.25
B8-PEG-fMLF5.5 0.5 5.3 2.75 10.6
B8-PEG-fMLF8 0.18 5.0 1.44 27.8
PEG-aspartate-fMLF4 1.1 - 4.4 -
PEG-aspartate-fMLF4-DIG4 1.2 5.9 4.8 4.92